SLC5A2 and diabetes mellitus: Recently, the FDA approved two gliflozins for the treatment of diabetes mellitus in cats: velagliflozin in December 2022 (Bexacat®; Elanco) and velagliflozin (12) in July 2023 (Senvelgo®; Boehringer Ingelheim) both with high affinity for SGLT2 inhibition.